Literature DB >> 25677951

Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancers.

Bryan C Murray1, Michael T Peterson, Robert A Fecik.   

Abstract

Since their first report in 2000, tubulysins have sparked great interest for development as anti-cancer agents due to their exceptionally potent antiproliferative activity. Progress in the discovery and development of tubulysins, especially tubulysin conjugates, has quickly advanced despite limitations in their availability from Nature. In this Highlight, the key research on the isolation and structure determination, biosynthesis, bioactivity, structure-activity relationships (SAR), synthesis, and conjugates of tubulysins is presented.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25677951     DOI: 10.1039/c4np00036f

Source DB:  PubMed          Journal:  Nat Prod Rep        ISSN: 0265-0568            Impact factor:   13.423


  14 in total

Review 1.  Strategies and challenges for the next generation of antibody-drug conjugates.

Authors:  Alain Beck; Liliane Goetsch; Charles Dumontet; Nathalie Corvaïa
Journal:  Nat Rev Drug Discov       Date:  2017-03-17       Impact factor: 84.694

2.  Molecular and functional characterization of myxobacteria isolated from soil in India.

Authors:  Shiv Kumar; Arun Kumar Yadav; Priyanka Chambel; Ramandeep Kaur
Journal:  3 Biotech       Date:  2017-05-31       Impact factor: 2.406

3.  Macrocyclic peptides decrease c-Myc protein levels and reduce prostate cancer cell growth.

Authors:  Archana Mukhopadhyay; Laura E Hanold; Hamsa Thayele Purayil; Solomon A Gisemba; Sanjeewa N Senadheera; Jane V Aldrich
Journal:  Cancer Biol Ther       Date:  2017-07-10       Impact factor: 4.742

4.  Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.

Authors:  Carolyn A Leverett; Sai Chetan K Sukuru; Beth C Vetelino; Sylvia Musto; Kevin Parris; Jayvardhan Pandit; Frank Loganzo; Alison H Varghese; Guoyun Bai; Bin Liu; Dingguo Liu; Sarah Hudson; Venkata Ramana Doppalapudi; Joseph Stock; Christopher J O'Donnell; Chakrapani Subramanyam
Journal:  ACS Med Chem Lett       Date:  2016-08-26       Impact factor: 4.345

5.  Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.

Authors:  Leanna R Staben; Shang-Fan Yu; Jinhua Chen; Gang Yan; Zijin Xu; Geoffrey Del Rosario; Jeffrey T Lau; Luna Liu; Jun Guo; Bing Zheng; Josefa Dela Cruz-Chuh; Byoung-Chul Lee; Rachana Ohri; Wenwen Cai; Hongxiang Zhou; Katherine R Kozak; Keyang Xu; Gail D Lewis Phillips; Jiawei Lu; John Wai; Andrew G Polson; Thomas H Pillow
Journal:  ACS Med Chem Lett       Date:  2017-09-05       Impact factor: 4.345

6.  Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Authors:  L Nathan Tumey; Carolyn A Leverett; Beth Vetelino; Fengping Li; Brian Rago; Xiaogang Han; Frank Loganzo; Sylvia Musto; Guoyun Bai; Sai Chetan K Sukuru; Edmund I Graziani; Sujiet Puthenveetil; Jeffrey Casavant; Anokha Ratnayake; Kimberly Marquette; Sarah Hudson; Venkata Ramana Doppalapudi; Joseph Stock; Lioudmila Tchistiakova; Andrew J Bessire; Tracey Clark; Judy Lucas; Christine Hosselet; Christopher J O'Donnell; Chakrapani Subramanyam
Journal:  ACS Med Chem Lett       Date:  2016-06-22       Impact factor: 4.345

7.  Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.

Authors:  Michal Stark; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2017-07-25

8.  Stereoselective access to tubuphenylalanine and tubuvaline: improved Mn-mediated radical additions and assembly of a tubulysin tetrapeptide analog.

Authors:  Gregory K Friestad; Koushik Banerjee; Jean-Charles Marié; Umesh Mali; Lei Yao
Journal:  J Antibiot (Tokyo)       Date:  2016-02-17       Impact factor: 2.649

9.  The pretubulysin-induced exposure of collagen is caused by endothelial cell retraction that results in an increased adhesion and decreased transmigration of tumor cells.

Authors:  Rebecca Schwenk; Tanja Stehning; Iris Bischoff; Angelika Ullrich; Uli Kazmaier; Robert Fürst
Journal:  Oncotarget       Date:  2017-09-08

10.  Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.

Authors:  Joseph A Reddy; Ryan Dorton; Alicia Bloomfield; Melissa Nelson; Christina Dircksen; Marilynn Vetzel; Paul Kleindl; Hari Santhapuram; Iontcho R Vlahov; Christopher P Leamon
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.